Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
HYZAAR® 50/12.5(LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS)HYZAAR® 100/12.5(LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS)HYZAAR® 100/25(LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS)
Medication labelWhy this: Advisory · dailymed-prescription
HYZAAR is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, and DOSAGE AND ADMINISTRATION). HYZAAR is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See PRECAUTIONS, Race, CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Losartan Potassium, Reduction in the Risk of Stroke, Race, and DOSAGE AND ADMINISTRATION.)
- generic_name
- losartan potassium and hydrochlorothiazide
- product_names
- losartan potassium and hydrochlorothiazide
- ndc
- 54868-3866, 54868-4341, 54868-5705, 0006-0717, 54868-3866-0, 54868-3866-1, 0006-0745, 54868-5705-0, 0006-0747, 54868-4341-0
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en